Cisplatin reacts with DNA, and thereby likely generates a characteristic pattern of somatic mutations, called a mutational signature. Despite the widespread use of cisplatin in cancer treatment and its role in contributing to secondary malignancies, its mutational signature has not been delineated. Delineation of the mutational signature of cisplatin would enable identification of cisplatin-induced secondary malignancies, and consequently improve screening for secondary malignancies after cisplatin chemotherapy.
Introduction
For 40 years, cisplatin and its derivatives have been cornerstones of the treatment of almost every type of cancer (Dasari and Tchounwou 2014; Dugbartey et al. 2016 ). However, cisplatin treatment often causes numerous side effects, including hepatotoxicity (Waseem et al. 2015; Dugbartey et al. 2016) , and it increases the risk of developing secondary malignancies. For example, cisplatin based treatments almost always cure testicular cancers, but increase the risk of developing a solid tumor later in life 1.8-fold (Travis et al. 2005) , and cisplatin treatment of several types of cancers increases the incidence of secondary leukemia's (Ratain et al. 1987; Kushner et al. 1998 ). Cisplatin's therapeutic properties depend partly on its DNA damaging activity, and the risk of secondary malignancies presumably stems from the consequent mutagenesis (Choi et al. 2014 ). This highlights the importance of understanding cisplatin mutagenesis and how it promotes carcinogenesis. This also highlights the need for a biomarker to identify cisplatin-induced secondary malignancies.
The mechanisms of cisplatin induced DNA damage have been extensively studied.
When cisplatin enters the cells, its two chloride atoms are hydrolyzed, resulting in two positive charges (Masters and Koberle 2003; Behmand et al. 2015) . Although the hydrolyzed molecule presumably reacts with many molecules in the cell, its therapeutic cytotoxicity is generally considered to stem from reactions with the N7 atoms of purine bases in DNA (Harrington et al. 2010; Dasari and Tchounwou 2014; Behmand et al. 2015) . Most cisplatin-DNA adducts are crosslinks between two adjacent guanines (GpG, 65%) or between an adenine and a guanine (5'-ApG-3', 25%). Mono-adducts and interstrand crosslinks are much rarer (Jamieson and Lippard 1999; Masters and Koberle 2003; Enoiu et al. 2012) . Cisplatin induced DNA intrastrand crosslinks and mono-adducts are repaired through nucleotide excision repair (NER) (Zamble et al. 1996; Reardon et al. 1999; Hu et al. 2016) . Interstrand crosslinks are the most difficult to repair and the most cytotoxic, because they covalently link the two strands of the DNA helix and consequently block transcription and replication (Jamieson and Lippard 1999; Masters and Koberle 2003; Enoiu et al. 2012; Hashimoto et al. 2016; Roy and Scharer 2016) . The mechanisms of interstrand-crosslink repair have not yet been fully elucidated but appear to be complicated (Hashimoto et al. 2016; Roy and Scharer 2016) .
Cisplatin likely causes a characteristic pattern of single-nucleotide substitutions (SNSs), known as a mutational signature, along with possible additional features including fewer mutations on the transcribed strands of genes and association with small insertions and deletions (indels) or dinucleotide substitutions (DNSs) (Alexandrov et al. 2013a ).
Currently 30 mutational signatures are widely recognized, and they have a variety of known, suspected or unknown causes (Alexandrov et al. 2013a; Alexandrov et al. 2013b; Wellcome Trust Sanger Institute 2016) . Mutational signatures can serve as biomarkers for endogenous mutagenic processes and exposures that led to the development of tumors. We hypothesize that cisplatin's mutational signature can serve as biomarker to identify cisplatin-induced secondary malignancies, to improve screening for secondary malignancies after cisplatin chemotherapy, and to identify which tissues are especially vulnerable to secondary malignancies after cisplatin treatment.
Two previous studies investigated the mutational signature of cisplatin, one in Caenorhabditis elegans and one in a chicken (Gallus gallus) B-cell cell line (Meier et al. 2014; Szikriszt et al. 2016) . Although both studies reported mutational signatures with primarily C>A mutations, the SNS signature were otherwise dissimilar: the C. elegans signature was dominated by CCA>CAA and CCT>CAT mutations, while the chicken signature was dominated by NCC>NAC mutations (where N is any base). This lack of similarity may have been due to the different model systems used, to the low numbers of mutations in the C. elegans study, or to experimental differences between the studies. In any case, these studies failed to unequivocally elucidate the mutational signature of cisplatin.
Therefore, we studied cisplatin mutations in MCF-10A cells, a non-tumorigenic human breast epithelial cell line. Here we report the extensive characterization of the cisplatin signature obtained, as well as its discovery in hepatocellular carcinomas and esophageal adenocarcinomas in patients previously exposed to cisplatin.
Results
Cisplatin's single-nucleotide substitution signature
We exposed two independent cultures of MCF-10A cells to 0.5 µM and 1 µM of cisplatin once a week for 8 weeks. Single cells were isolated and expanded for whole-genome sequencing and mutational analysis. We sequenced untreated MCF-10A and 3 cisplatin-exposed clones from each concentration, one exposed for 4 weeks and 2 exposed for 8 weeks. Mean coverage was >33x, and in total we identified 30,153 SNSs and 1,708 indels (Supplementary Table 1 ).
The SNS mutation spectra from all 6 clones were highly similar ( Figure 1A , Supplementary Table 2 , all Pearson correlations > 0.958 and cosine similarities > 0.971). The most prominent features were two C>T peaks (CCC>CTC and CCT>CTT) and four T>A peaks (CT>CA). There were also substantial numbers of C>A mutations (~22.8% of all mutations), and peaks at GCC>GAC and GCC>GGC. Figure 1B and Supplementary Figure 1B display the signatures as mutation rates per trinucleotide, which better reflects the sequence specificity of mutational processes because they are not affected by differences in trinucleotides abundances. For example, Figure 1B shows more prominent CCC>CTC peaks and reveals that the gap at CCG>CTG in Figure 1A reflects the low abundance of CCG trinucleotides in the genome rather than reduced mutagenicity.
In addition to consistent patterns of the bases immediately 5' and 3' of cisplatin SNSs, there were also many preferences 2 bp 5' and 3' of the SNSs (Figure 1C , Supplementary figure 2). For example, CT>CA mutations were usually preceded by an A (ACT>ACA). Similarly, CC>CT mutations were usually preceded by a pyrimidine (YCC>YCT). These and other preferences at the -2 bp or +2 bp positions were statistically significant (Supplementary figure 3).
Associations of cisplatin-induced single-nucleotide substitutions with genomic features
Many mutational processes cause fewer mutations due to damage on the transcribed strands of genes than on the non-transcribed strands. This is termed transcription strand bias and is due to transcription-coupled nucleotide excision repair (TC-NER) of adducted bases in the transcribed (antisense) strands. Since cisplatin forms adducts on purines, we would expect reduced numbers of mutations when G and A is on the transcribed strand (C and T are on the sense strand). As expected, C>A, C>T and T>A SBSs were strongly reduced on the non-transcribed strand ( Supplementary Figure 4) (Fousteri and Mullenders 2008; Harrington et al. 2010; Dasari and Tchounwou 2014; Behmand et al. 2015; Hu et al. 2016 ). Also consistent with TC-NER, strand bias for C>A, C>T and T>A mutations was stronger in more highly expressed genes (p = 2.20×10 -16 , one-sided Chi-squared test for all MCF-10A clones combined, Figure 2A , Supplementary Figure 5 ). Finally, TC-NER efficiency decreases from the 5' to the 3' ends of transcripts (Conaway and Conaway 1999; Hu et al. 2015; Huang et al. 2017) . Consistent with this, strand bias for C>A, C>T and T>A SNSs decreased toward the 3' ends of transcripts (p = 2.46×10 -12 , logistic regression for all MCF-10A clones combined, Figure 2B , Supplementary Figure 6 ).
For some mutational processes, the intensity of mutagenesis is associated with chromatin state (Polak et al. 2015; Seplyarskiy et al. 2015; Kaiser et al. 2016) . Additionally, there is increased cisplatin adduct formation in open chromatin compared to closed chromatin (Hu et al. 2016 ). In the MCF-10A cells, regions with histone marks indicative of active promoters, enhancers and actively transcribed genes were less highly mutated , and regions with histone marks associated with heterochromatin and transcriptional repression were more highly mutated ( Figure 2C ).
DNSs in cisplatin signature
To investigate the presence of DNSs in the cisplatin genomes we selected all adjacent SNS, and verified that both SNS were on the same reads (see Materials and Methods). We identified 1,106 DNSs in the cisplatin genomes, of which most were mutations from CC, CT, TC and TG ( Figure 3A , Supplementary Figure 7 ). We hypothesized that mutations from CC, CT, and TC are consequences of intrastrand crosslinks at GpG, ApG and GpA, and that mutations from TG were consequences of diagonally-offset interstrand guanine-adenine crosslinks T
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(crosslinked bases in bold). Mutations from AT, TA and TT were rare, which is consistent with previous reports that cisplatin does not induce adenine-adenine crosslinks ( Supplementary Table 3 ) (Jamieson and Lippard 1999; Masters and Koberle 2003) .
The proportion of SNSs involved in DNSs ranged from 6.2% to 8.5%. To relate this to other mutagenic processes known to be associated with DNSs, we examined the percentage of SNSs involved in DNSs associated with COSMIC Signatures 4 (smokingrelated) and 7 (due to UV exposure) (Wellcome Trust Sanger Institute 2016). We studied Signature 4 in 24 lung adenocarcinomas (Imielinski et al. 2012 ) and Signature 7 in 112 melanomas (Zhang et al. 2011) . In both tumor types, the percentage of SNSs involved in DNSs was significantly lower than in cisplatin ( Figure 3B , mean 3.5%, sd=1.4%, p=6.7×10 -7 and mean=3.3%, sd=1.6%, p=2.1×10 -8 respectively, 2-sided t-tests versus cisplatin). We hypothesize that this high proportion of DNSs in cisplatin stems from cisplatin's propensity to form intrastrand crosslinks between adjacent bases and to form diagonally offset interstrand crosslinks.
To investigate possible sequence context preferences of cisplatin DNSs, we plotted 1bp contexts of each reference dinucleotide, irrespective of the mutant allele ( Figure 3C , Supplementary Figure 8 ). There was strong enrichment for TC and TG DNSs in TCT and TGG contexts. Both TC and TG DNSs were further enriched for a 5' flanking purine (Supplementary Figure 8, 9) . The strongest sequence context preference was for CC>NN mutations, 49.8% of which occur in GCCT context (Supplementary Figure 8, 9) . As methodological control, we also evaluated ±1bp sequence context for DNSs associated with COSMIC Signatures 4 and 7. DNSs associated with COSMIC Signature 7 showed strong sequence context preference for most mutation classes, including CC>NN, CT>NN and TT>NN (Supplementary Figure 10) . The context preferences were very different however, from those of cisplatin DNSs. By contrast, DNSs associated with COSMIC Signature 4 had only weak sequence context preferences (Supplementary Figure 10 ).
To assess transcription strand bias in DNSs, we examined separately the mutations hypothetically involving interstrand purine-purine crosslinks, predominantly mutations from the T
5′ 3′
C 5′ 3′ configuration, and the mutations hypothetically involving intrastrand purine-purine crosslinks (predominantly mutations from CC, CT, and TC). We observed transcription strand bias at the potential intrastrand crosslink sites other than TC in most of the MCF-10A clones. (Figure 3D , Supplementary Figure 11 ). There was no evidence of transcription strand bias at potential interstrand crosslink sites. As methodological control, we also evaluated transcription strand bias for DNSs associated with COSMIC Signatures 4 and 7, in which we also detected strand bias (Supplementary Figure 12 ).
Likely cisplatin mutational signature in human tumors
We examined publicly available human tumor mutation data for evidence of the experimental cisplatin signature. Notably, mutational signature W6, which was reported in the whole genome sequences of hepatocellular carcinomas (HCCs), resembles the experimental cisplatin signature (cosine similarity = 0.803, Supplementary Figure 13 ) (Fujimoto et al. 2016) . Although the relative proportions of the major substitution classes (C>A, C>T and T>A) are rather different between Signature W6 and our experimental cisplatin signature, the profiles within each mutation class are similar (cosine similarities for C>A, C>T and T>A of 0.887, 0.921 and 0.980 respectively, Supplementary Figure 13 ).
Given this resemblance, we analyzed whole-genome trinucleotide spectra from Japanese and Hong Kong HCCs (Kan et al. 2013; Fujimoto et al. 2016 ), using the mSigAct signature presence test (see Materials & Methods) . Out of 342 HCCs, 9 showed evidence of cisplatin exposure (Table 1 , Figure 4A , Supplementary Figure 14 , compare with Figure 1A ). To further assess presence of cisplatin mutagenesis, we also examined the dinucleotide spectra of these samples ( Figure 4B , Supplementary Figure 15 , compare with Figure 3A) . 7 of the 9
HCCs with the cisplatin SNS spectrum also had high cosine similarities between their DNS spectra and the cisplatin signature ( Figure 4C ) and high numbers of DNSs relative to their total SNS load (ranging from 2.9 to 6.2%, with the median of all HCCs at 1.6%, Supplementary Figure 16A ).
We also analyzed the mutational spectra of 140 esophageal adenocarcinomas (ESADs), of which 68 had been treated with cisplatin prior to surgery (Noorani et al. 2017 ).
SNS analysis suggested 3 of the cisplatin treated ESADs had the cisplatin signature, whereas we found no evidence of cisplatin mutagenesis in any of the untreated ESADs. Of the 3 ESADs identified in the SNS analysis, the DNS analysis supported likely cisplatin exposure in 2 (Table 1 , Supplementary Figures 16B, 17, 18 ).
We further investigated whether DNS analysis could identify cisplatin-exposed tumors that were missed by the SNS analysis. We performed semi-supervised nonnegative matrix factorization (ssNMF) on all tumors with ≥25 DNSs, specifying the cisplatin DNS signature as one input signature and asking for discovery of 1 to 7 additional signatures (Materials & Methods, Supplementary Figures 19, 20) . We recovered all 7 previously identified cisplatin-positive HCCs. Additionally, we identified RK140 to have >50% of DNSs attributed to cisplatin by ssNMF. Looking closer into this sample revealed a high cosine similarity between the DNS spectrum with that of the experimental data, as well as a relatively high proportion DNSs (Table 1 , Supplementary Figure 16A ). Although the SNS based p value was not significant after multiple-testing correction, we nevertheless concluded based on the combined SNS and DNS analyses that RK140 showed strong (Table   1 ). All 7 had received cisplatin-based DEB-TACE (transarterial chemoembolization using drug eluting beads) several months prior to surgical resection. In addition to TACE treatment for the sampled tumor, RK205, RK241 and RK256 also had had prior malignancies (Table   1 ). The variant allele frequencies of the cisplatin-associated DNSs were similar to the variant allele frequencies of all other SNSs, including those not likely due to cisplatin exposure ( Supplementary Table 4 ). This suggested that the cisplatin was an early event in tumorigenesis, which is concordant with rapid clonal expansion after DEB-TACE treatment (Zen et al. 2011) . Notably, the 2 HCCs we suspected to be false-positives based on the DNS spectra (RK047 and RK309) had no record of treatment with cisplatin prior to surgery.
Discussion
We have delineated the in vitro multidimensional mutational signature of cisplatin with extensive characterization of patterns of SNSs in tri-and pentanucleotide contexts and their associations with genomic features, as well as the patterns of DNSs and flanking bases. We began with in vitro delineation because it directly links mutational signatures to etiologies and because it generates signatures that are relatively unobscured by other mutational processes. We analyzed whole genome data because these provide >50 times more mutations than exomes and consequently greater stability and reproducibility of signatures. Indeed, whole genome data are practically essential for analysis of DNSs, which are rare compared to SNSs. Importantly, with the experimentally delineated SNSs and DNSs signatures in hand, we were able to detect cisplatin mutagenesis in HCCs and ESADs with high confidence. All hepatocellular carcinomas for which clinical data were available and both esophageal cancers indeed had histories of prior cisplatin treatment. We therefore conclude that the mutational signature established here serves as a biomarker for cisplatin mutagenesis that can detect cisplatin-induced secondary malignancies.
Prior to this study, 2 different experimentally elucidated mutational signatures of cisplatin were reported, one in Caenorhabditis elegans, and the other in cultured chicken B-cells (DT40) (Meier et al. 2014; Szikriszt et al. 2016 ). Both studies found primarily C>A mutations, but in terms of SNSs in trinucleotide context, the signatures bore no resemblance to each other or to the MCF-10A signature ( Supplementary Figure 22) . Because of the low mutation count in the C. elegans data, this was true for both the DNA repair proficient worms (N2) as well as for all worms combined. Like the treated MCF-10A cells, the exposed worms and DT40 cells had relatively high numbers of DNSs relative to SNSs, with many at potential intrastrand crosslink sites (ApG, GpA and GpG). However, in neither system was it possible to discern the MCF-10A cisplatin signature in the SNS mutation spectra, due to the high number of C>A mutations ( Supplementary Figure 22) . We also note that the C>A mutations in the treated worms and DT40 cells do not resemble any currently known mutational signature or artefact.(Wellcome Trust Sanger Institute 2016) The differences between the MCF-10A cisplatin signature and the C. elegans and DT40 signatures might stem from the different model organisms used, which may differ in DNA damage susceptibility and characteristics of DNA repair and replication errors. In any case, the differences between the previously published cisplatin spectra and the MCF-10A cisplatin signature emphasize the need for standardization of in vitro mutational signature models. We propose that it is prudent to use human cell lines for experimental elucidation of mutational signature etiology, to avoid possible differences in translesion synthesis and DNA repair proficiencies between organisms.
Mutational processes reflect the cumulative effect of 3 steps: (i). DNA damage (for cisplatin, adduct formation), (ii) DNA repair (for cisplatin, NER), which may or may not correct the damage, and (iii) if DNA repair fails, translesion synthesis across the damaged base or bases may replicate the DNA correctly or incorrectly, in the latter instance creating a mutation.
In this study, while known patterns of adduct formation did not predict the patterns of substitutions ( Figure 5 ), we can nevertheless postulate models that explain the observed mutations by combining our knowledge of adduct formation and models of how DNA replication and translesion synthesis might behave (II and III).
First, despite high proportions of DNSs relative to SNSs, SNSs still greatly outnumbered the DNSs ( Figure 5A ). We postulate that these SNSs are formed by correct translesion synthesis opposite one of the purines of the purine-purine intrastrand crosslinks, and misincorporation occurring opposite the other, as has been shown for UV-induced intrastrand crosslinks (McCulloch et al. 2004 ). This is supported by the high number of SNSs at potential intrastrand crosslink sites: 85% of the 30,153 SNSs are at GpG, GpA or ApG sites ( Supplementary Figure 23) .
Second, the relative abundance of the different types of DNSs did not correspond to the reported ratios of intrastrand and interstrand adducts at their respective dinucleotides (compare the right pie-charts of Figures 5A,B , with graphical representations of the most prominent adducts in Figure 5C ). For example, crosslinks at ApG are half as abundant than at GpG, but DNSs from AG:CT were 1.5-times more common than from GG:CC. This suggests that repair of GpG crosslinks is more efficient, or that translesion synthesis past these adducts is less error-prone. As another example, the 2-fold higher number of DNSs from AG:CT than GA:TC does not correspond to the relative frequencies of ApG and GpA adducts (Murray et al. 1992; Mantri et al. 2007 ). Furthermore, 28.2% of DNSs were in potential interstrand crosslink sites, while these represent <5% of cisplatin-adducts (Jamieson and Lippard 1999; Enoiu et al. 2012 ). However, the higher proportion of DNS putatively due to interstrand crosslinks is consistent with interstrand crosslinks being more damaging than intrastrand crosslinks (Andreassen and Ren 2009; Hashimoto et al. 2016; Roy and Scharer 2016) .
In this study, combined SNS and DNS information was crucial for high-confidence 
Materials & Methods

Cell line exposure
MCF-10A cells were obtained from the ATCC. Culturing was performed in DMEM/F12 medium supplemented with 10%,FBS, 10 ng/mL insulin, 20 ng/mL EGF, 0.5 µg/mL hydrocortisone, 50 ng/µL penicillin and 50 U/mL streptomycin. For cisplatin exposure, 60,000 cells/well were seeded at day 0 in a 6-wells plate. On day 1 cisplatin was added to final concentrations of 0.5 µM and 1 µM. At day 7, cells were trypsinized and counted, and per population, 60,000 were seeded in a new 6-wells plate. This process was repeated 8 times. As mutagenesis requires DNA replication, the proliferation rate was monitored. The proliferation rate of 0.5 µM and 1 µM treated cells was 66% and 15% of the untreated population (p < 0.001, Supplementary Figure 24 ). After 4 weeks and 8 weeks, cells were expanded, and single cells were isolated through FACS-sorting directly into a 96-well plate with culture medium. These single cell clones were expanded for DNA isolation and wholegenome sequencing.
Whole-genome sequencing
The MCF-10A cell line was sampled at the start of the cisplatin exposure. DNA 
Alignment and variant calling
Read alignment to hs37d5 was done using BWA-MEM, followed by PCR duplicate removal and merging using Sambamba (v0.5.8) (Tarasov et al. 2015 Figure 25 .
DNSs were identified as 2 adjacent SNSs. As primary QC we checked that the variant allele frequencies of both SNSs were equal. Secondly, we re-called the genomes using Freebayes, which calls DNSs when the SNSs are in the same reads (Garrison 2012 
Statistical analysis of enrichment of mutations in pentanucleotide context
To statistically test for enrichment or depletion of SNSs in each pentanucleotide context we used a binomial test against the null hypothesis that the proportion of a given pentanucleotide that contained a given SNS was the same as the proportion of all pentanucleotides with that SNS. We take as an example A:T>C:G SNS at the center of pentanucleotide CCACC:GGTGG. There were a total of 5,639 T>A mutations in the sequenced portions of the genome, of which 10 were in a CCACC:GGTGG pentanucleotide.
In total there were 1,491,086,541 pentanucleotide sites centered on A:T in the sequenced regions of the genome, of which 6,784,989 were CCACC:GGTGG. We then used the R function call binom.test(x = 10, n=5,639, p = (6,784,989 / 1,491,086,541)), which yielded p < 7.12×10 -4 . The alternative hypothesis was that the proportions were not equal.
Analysis of association between cisplatin mutations and genomic features
As histone ChIP-seq data for MCF-10A was not available, we obtained processed 
Sources of publicly available sequencing data
This study used whole genome sequencing data from 264 HCCs from Japan (Fujimoto et al. 2016 ) and 78 from Hong Kong (Kan et al. 2013 ) and 140 ESADs (Noorani et al. 2017) . Additionally, we used whole genome sequencing data of 24 lung adenocarcinomas (Imielinski et al. 2012 ) and 112 melanomas. For the HCCs, ESADs and melanomas, simple somatic mutation data was downloaded from the ICGC data portal (https://dcc.icgc.org/, release 18, March, 2015) . The 78 Hong Kong HCCs were re-analyzed as described previously (Huang et al. 2017 ).
Analysis of the SNS cisplatin signature exposure in tumors
We used the mSigAct signature.presence.test function to assess possible presence of the experimental cisplatin signature in the publicly available mutational spectra of HCCs 
NMF on DNS spectra
To assess the effect of cisplatin on primary tumors based on DNSs, we developed a customized semi-supervised NMF (ssNMF) method that incorporated the method from (Schmidt 2007) into the NMF code from (Alexandrov et al. 2013b) ; Supplementary Code 2 provides the patch file. We use a customary notation for NMF, ≈ , in which is the matrix of observed mutational spectra, , is the matrix of mutational signatures, and is the matrix of "exposures". ssNMF treats , the signature matrix, as composed of two segments:
, which specifies the known, fixed signatures, and , which is computed by NMF. ssNMF updates only and . We ran ssNMF separately on (i) , the ESAD spectra plus the MCF-10A spectra and (ii) , the combined spectra from the HCCs, lung adenocarcinomas, and the MCF-10A treated cells. We ran ssNMF on each of and , asking for 2, 3, 4, 5, 6, 7 and 8 signatures (i.e. number of columns of ). In both cases consisted of a fixed signature that was the sum of the DNS spectra of all MCF-10A divided by the total DNS count of all spectra. Using the signature stability and average Frobenius reconstruction error approach described in (Alexandrov et al. 2013b ), we chose 3 signatures for both of and (Supplementary Figures 19, 20) . 
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Data availability
Sequencing reads for the cisplatin exposed MCF-10A clones are available at the European Nucleotide Archive (http://www.ebi.ac.uk/ena) under accession number PRJEB21971. Table 1 ). (CC>NN, CT>NN, TC>NN and TG>NN) . The total number of DNSs per mutation class is indicated in parentheses. Color intensity is relative to the number of mutations with that sequence context, normalized for tetranucleotide abundance in the genome. The vertical axis is the preceding base, the horizontal axis is the following base. Some prominent enrichments in sequence context are indicated (GCCT>GNNT, NTCT>NNNT and NTGG>NNNG). The full sequence context preference plots, both raw counts and normalized for tetranucleotide abundance in the genome are shown in Supplementary Figure 8. (D) Transcription strand bias of dinucleotide substitutions.
Figure legends
Potential intrastrand crosslink sites are shown in blue, potential interstrand crosslink sites are shown in red. (52.1%), and CT mutations showed extremely strong preference for a T either preceding or following the mutated dinucleotide (79.5%). The strongest tetranucleotide context preference was observed for TA mutations, which prefer ATAA context (46.9%), and CG mainly occur in TCGA context (50.4%).
Supplementary Figure 11: Transcription strand bias of DNSs in cisplatin treated
MCF-10A clones. The total number of dinucleotides eligible for transcription strand bias analysis is displayed in parentheses. Figure 12 : Transcription strand bias of DNSs in 3 lung adenocarcinomas and 3 melanomas. Contrary to the cisplatin DNSs, both the smoking and UV associated DNSs displayed transcription strand bias. The UV associated dinucleotides showed a decrease of CC>TT mutations on the transcribed strand, as CC crosslinks induced by UV are repaired by TC-NER. Similarly, smoking associated dinucleotides showed transcription strand bias with a decrease of CC>AA mutations on the untranscribed strand. This fits the prior knowledge that smoking causes GG intrastrand crosslinks, which are repaired by TC-NER if they are located on the transcribed strand. As we display the DNSs as CC>AA, the strand bias is reversed. Figure 13 : Comparison of signature W6 with the cisplatin mutational signature. Figure 14 : SNS mutation spectra for HCCs that were identified to be positive for the cisplatin mutational signature in the SNS analysis. Figure 15 : DNS mutation spectra for HCCs that were identified to be positive for the cisplatin mutational signature in the SNS analysis, displayed as mutations per million dinucleotides. For the ESADs, samples with known prior exposure to platinum-based chemotherapeutics are shown as circles; samples without prior platinum-based treatment are shown as crosses. Figure 17 : SNS mutation spectra for ESADs that were identified to be positive for the cisplatin mutational signature in the SNS analysis. Figure 18 : DNS mutation spectra for ESADs that were identified to be positive for the cisplatin mutational signature in the SNS analysis, displayed as mutations per million dinucleotides. 
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